AI Signal Dashboard
Last updated: 11 hours ago
Top Undervalued
+0.3¢
(No)
Will Pfizer (PFE) beat quarterly earnings? AI analysis: • +0.3¢ undervalued • Live Prediction Market fair value & mispricing alerts.
Undervalued Options Insights:
Based on the latest market consensus and analyst estimates, Pfizer's (PFE) Q1 2026 non-GAAP EPS expe...
🔓 Log in to see more
Real-time High Yield Opportunities
View MoreAll
Outcomes
Market
Price
AI Fair
Value
Value
Edge
YesNo
95.25¢
4.75¢
95¢
5¢
0¢
+0.3¢
⚠️ Risk Warning: Live data may lag! Prices can shift instantly due to news or low liquidity. Before trading, use AI Chat for [Live Recalculate], [Check Liquidity], [Trollbox Radar], or review [Fair Value Logic] to verify.
Hedging
PFE
Whether Pfizer (PFE) beats EPS estimates will directly impact its stock price, typically causing a medium-level (score 3) movement for the individual stock upon earnings release. The impact on the broader S&P 500 index would be negligible (score 1).
Movers
April 29, 2026 - April 30, 2026, the price of Option_'Yes' surged from 76c to 96.5c, as analysts revised their Q1 EPS estimates for Pfizer upward to around $0.74, boosting market confidence that it would beat the $0.72 strike.
April 28, 2026 - April 30, 2026, the price of Option_'Yes' surged from 50c to 87c, as the market regained confidence in Pfizer's ability to beat earnings estimates after a brief panic, likely based on new guidance or analyst re-affirmations.
April 27, 2026 - April 28, 2026, the price of Option_'Yes' plummeted from 85c to 50c, likely due to a market repricing of Q1 earnings expectations, potentially triggered by analyst downgrades or recent negative sector data.
April 24, 2026 - April 27, 2026, the price of Option_'Yes' climbed steadily from 67.5c to 85c, as the market initially held an optimistic view that Pfizer would continue its trend of earnings beats.